China has approved Pfizer’s (PFE) GLP-1 treatment Xianweiying for weight management in adults, Andrew Silver of Reuters reports, citing a WeChat post from the company. Sciwind, Pfizer’s licensing partner, in a prior statement said the deal was “an important first step to advance Pfizer’s global strategy in the metabolic field in China.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Weight-Loss Drug Approved in China — Up Against Generic Rivals
- Mixed options sentiment in Pfizer with shares down 0.39%
- Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
- ParaZero appoints Bat-Sheva Noy as VP, global sales
- Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value